Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Cardiotoxicity 4Sarcoma 3Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Localized Extraskeletal Ewing Sarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Ganglioneuroblastoma 1Burkitt Lymphoma 1

Interventions

Etoposide 6Ifosfamide 5Vincristine 4Radiotherapy 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Doxorubicin 4Cyclophosphamide 4Topotecan 2trioctyl phosphine oxide 1indolepropanol phosphate 1imetelstat 1etoposide phosphate 1Vinorelbine 1Vinblastine 1Trabectedin 1Thrombopoietin 1Radiosurgery 1Radiation 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Microarray Analysis 1Mesna 1MLN 8237 1Irinotecan 1Immunohistochemistry 1Glutamine 1Gene Expression Profiling 1GRN163L peptide 1Electroacupuncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neuroectodermal Tumors, Primitive, Peripheral × Dexrazoxane × Clear all
NCT00334867 2013-06-28

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Children's Oncology Group

Phase 3 Withdrawn
Sarcoma

Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡